FDA approves Wilserdly with everolimus, cutting breast cancer progression risk 62%
Key Facts
The U.S. Food and Drug Administration approved Wilserdly, known generically as giredestrant, with everolimus on November 16, 2026, to treat adults with locally advanced or metastatic breast cancer, according to an FDA notice. The approval is limited to tumors that are estrogen receptor-positive, HER2-negative and carry an ESR1 mutation confirmed by an approved test. It covers patients whose disease recurred after adjuvant endocrine therapy, or whose disease progressed after at least one treatment regimen in the metastatic setting. The approval places the treatment in a defined patient subgroup rather than authorizing it for all cases of advanced breast cancer. Roche said the regimen is oral and does not require injections.
Among patients with ESR1 mutations whose disease had previously progressed after treatment with a CDK4/6 inhibitor, the combination of Wilserdly and everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus, Roche said. The hazard ratio was 0.38, with a 95% confidence interval of 0.27 to 0.54 and a p-value of p<0.0001. The FDA said median progression-free survival was 10 months in the giredestrant and everolimus arm, versus 5.5 months in the arm receiving physician's choice of treatment with everolimus. The objective response rate was 27% with the combination, compared with 14% in the control arm. Overall survival data were immature when the progression-free survival analysis was conducted, according to the FDA.
The FDA's review was based on evERA, a randomized, open-label, multicenter Phase 3 trial that compared giredestrant plus everolimus with standard endocrine therapy plus everolimus in patients previously treated with a CDK4/6 inhibitor and endocrine therapy, Roche said. The study included 373 adults with locally advanced or metastatic breast cancer, including 207 patients whose tumors carried an ESR1 mutation, according to the FDA. Announcing the study results in September 2025, Roche said the trial met both co-primary endpoints and showed statistically significant and clinically meaningful improvement in progression-free survival in the intention-to-treat and ESR1 mutation populations. The company added at the time that overall survival data remained immature, with a positive trend, and that follow-up would continue through the next analysis. In October 2026, Roche said the study data had been published in the New England Journal of Medicine and that additional analyses were presented at the 2026 American Society of Clinical Oncology meeting.
Roche said ESR1 mutations can be detected with an FDA-approved diagnostic test and occur in up to 40% of patients with hormone receptor-positive metastatic breast cancer. The company said these mutations drive resistance to hormonal therapy and disease progression, making their identification part of selecting patients eligible for the combination. The FDA authorized the FoundationOne Liquid CDx test as a companion diagnostic to identify breast cancer patients whose tumors carry ESR1 mutations. Levi Garraway, Roche's chief medical officer and head of global product development, described resistance to hormonal therapy as a "major challenge" for patients with advanced disease carrying an ESR1 mutation. He said the oral regimen may delay disease progression and can be taken at home. The FDA set the recommended giredestrant dose at 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
The most common adverse reactions among patients receiving giredestrant with everolimus include stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea, according to the FDA. The agency conducted its review under Project Orbis in collaboration with Health Canada and Israel's Ministry of Health. The approval decision was issued four weeks before the FDA's target date, the agency said. This approval is separate from another application for Wilserdly as adjuvant treatment for early-stage estrogen receptor-positive, HER2-negative breast cancer, covering stages I, II and III. The FDA set a target decision date of November 30, 2026, for that application, according to Roche. The company said additional regulatory submissions and development activities for the drug are under way in markets outside the United States.
RHHBY shares closed at $60.95 on November 16, 2026, according to EL7 data. The stock had closed at $60.30 on November 13, $60.50 on November 12, $60.57 on November 11 and $61.08 on November 10. The available data do not include the session high and low for November 16. The stock's move that day was not attributed to the approval. The next specified U.S. regulatory milestone remains the application for adjuvant treatment of early breast cancer, with an FDA target decision date of November 30, 2026.